Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians
Authors:
Open Access
- 25 November 2021
- journal article
- research article
- Published by Springer Nature in BioDrugs
- Vol. 36 (1) , 71-83
Abstract
Background The adoption of oncology biosimilars has been slow in the USA, which may be attributed in part to stakeholder perceptions and lack of operational guidance that supports favorable access to biosimilars. Objective Our objective was to understand the real-world implementation experiences with oncology biosimilars of US payers and healthcare professionals (HCPs) as their experience with biosimilars has evolved. Methods In-depth qualitative interviews with payers (n = 20) and HCPs (n = 17 physicians, n = 3 practice managers) were conducted. Payers included managed care organizations (MCOs), integrated delivery networks, and pharmacy benefit managers (PBMs). Physicians were affiliated with a healthcare network or were community based, specialized in hematology/oncology, and had prescribed oncology biosimilars. Audio transcripts of the interviews were coded using MaxQDA software to enable descriptive analysis of the qualitative data. Results Over 80.0% of physicians perceived the efficacy and safety of biosimilars to be highly comparable to that of originators. Up to 87.5% of physicians reported using biosimilars in > 50% of their treatment-naïve patients and were comfortable using biosimilars in all approved indications. To encourage utilization, 75.0% of MCOs/PBMs preferred biosimilars over originators in treatment-naïve patients and implementation via step therapy. Physician involvement in choosing biosimilars was minimal, which was largely dependent on practice protocols or insurance preferences. The major factor influencing payers’ coverage decisions and biosimilar adoption was potential cost savings. Conclusions US payers and physicians who have experience with biosimilars have favorable views of oncology biosimilars, particularly for treatment-naïve patients. A framework for integrating biosimilars into oncology practice is developing, primarily driven by insurance coverage, contracting, and cost benefits.Keywords
Funding Information
- Pfizer
This publication has 36 references indexed in Scilit:
- Clinical development of biologicals and biosimilars - safety concernsExpert Review of Clinical Pharmacology, 2017
- Biosimilars: Practical Considerations for PharmacistsAnnals of Pharmacotherapy, 2017
- Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty PhysiciansAdvances in Therapy, 2016
- Biosimilars: Opportunities to Promote Optimization Through Payer and Provider CollaborationJournal of Managed Care & Specialty Pharmacy, 2016
- Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees.2015
- Biosimilar Competition In The United States: Statutory Incentives, Payers, And Pharmacy Benefit ManagersHealth Affairs, 2015
- Barriers to market uptake of biosimilars in the USGenerics and Biosimilars Initiative Journal, 2014
- Formulary Selection Criteria for Biosimilars: Considerations for US Health-System PharmacistsHospital Pharmacy, 2014
- The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's ExperienceThe Oncologist, 2013
- How Many Interviews Are Enough?Field Methods, 2006